Loading...
|
Please use this identifier to cite or link to this item:
https://ir.cnu.edu.tw/handle/310902800/32256
|
| 標題: | Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma |
| 作者: | Wu, Wei-De
Chen, Pin-Shern
Omar, Hany A.
Arafa, El-Shaimaa A.
Pan, Hung-Wei
Jeng, Jingyueh
Hung, Jui-Hsiang |
| 貢獻者: | Chia Nan Univ Pharm & Sci, Dept Biotechnol
Univ Sharjah, Sharjah Inst Med Res
Univ Sharjah, Coll Pharm
Ajman Univ, Dept Clin Sci, Coll Pharm
Beni Suef Univ, Dept Pharmacol, Fac Pharm
Kaohsiung Vet Gen Hosp, Dept Med Educ & Res
Chia Nan Univ Pharm & Sci, Drug Discovery & Dev Ctr |
| 關鍵字: | Human Hepatoma-Cells
Kappa-B Pathway
Tumor-Growth
Signaling Pathway
Cancer Cells
Raf/Mek/Erk Pathway
Inhibits Migration
Over-Expression
Fruiting Bodies
Cycle Arrest |
| 日期: | 2018-08-27 |
| 上傳時間: | 2019-11-15 15:47:04 (UTC+8) |
| 出版者: | NATURE PUBLISHING GROUP |
| 摘要: | Hepatocellular carcinoma (HCC) has been recognized worldwide as one of the major causes of cancer death. The medicinal fungus Antrodia cinnamomea (A. cinnamomea) has been served as a functional food for liver protection. The aim of the present study was to investigate the potential activity of A. cinnamomea extracts as a safe booster for the anticancer activity of sorafenib, a multi-kinase inhibitor approved for the treatment of HCC. The biologically active triterpenoids in the ethanolic extracts of A. cinnamomea (EAC) were initially identified by HPLC/LC/MS then the different extracts and sorafenib were assessed in vitro and in vivo. EAC could effectively sensitize HCC cells to low doses of sorafenib, which was perceived via the ability of the combination to repress cell viability and to induce cell cycle arrest and apoptosis in HCC cells. The ability of EAC to enhance sorafenib activity was mediated through targeting mitogen-activated protein (MAP) kinases, modulating cyclin proteins expression and inhibiting cancer cell invasion. Moreover, the proposed combination significantly suppressed ectopic tumor growth in mice with high safety margins compared to single-agent treatment. Thus, this study highlights the advantage of combining EAC with sorafenib as a potential adjuvant therapeutic strategy against HCC. |
| link: | http://dx.doi.org/10.1038/s41598-018-31209-8 |
| 關聯: | Scientific Reports, v.8, 12914 |
| Appears in Collections: | [生物科技系(所)] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| 10.1007-s13197-018-3148-4.pdf | | 4992Kb | Adobe PDF | 647 | View/Open | | index.html | | 0Kb | HTML | 1473 | View/Open |
|
All items in CNU IR are protected by copyright, with all rights reserved.
|
